Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H10N3O4S.Na |
| Molecular Weight | 327.291 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].[O-]C(=O)C1=CS[C@H]2N1C(=O)\C2=C\C3=CN4CCOCC4=N3
InChI
InChIKey=RFSWVJXWZXQOSW-ZDFSRXSCSA-M
InChI=1S/C13H11N3O4S.Na/c17-11-8(12-16(11)9(6-21-12)13(18)19)3-7-4-15-1-2-20-5-10(15)14-7;/h3-4,6,12H,1-2,5H2,(H,18,19);/q;+1/p-1/b8-3-;/t12-;/m1./s1
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Relationship between β-lactamase production and resistance phenotype in Klebsiella pneumoniae strains. | 2017-07-06 |
|
| Establishment of in vitro susceptibility testing methodologies and comparative activities of piperacillin in combination with the penem {beta}-lactamase inhibitor BLI-489. | 2009-02 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00854009
Unknown
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
R56JYB8P8Z
Created by
admin on Mon Mar 31 18:18:28 GMT 2025 , Edited by admin on Mon Mar 31 18:18:28 GMT 2025
|
PRIMARY | |||
|
23697683
Created by
admin on Mon Mar 31 18:18:28 GMT 2025 , Edited by admin on Mon Mar 31 18:18:28 GMT 2025
|
PRIMARY | |||
|
623564-40-9
Created by
admin on Mon Mar 31 18:18:28 GMT 2025 , Edited by admin on Mon Mar 31 18:18:28 GMT 2025
|
PRIMARY |
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD